http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2190752-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0c627410c815ead42001cab3ef804df |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-65 |
| filingDate | 1995-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_866642df45252f31127847784cf946bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aa4cf87e6cf42c133eace45f4d74c6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f4fc0360abf58018915ead220c30090 |
| publicationDate | 1995-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2190752-A1 |
| titleOfInvention | Modified insulin-like growth factors |
| abstract | Modified forms of insulin-like growth factor (IGF) are provided which demonstrate improved pharmacological and biological properties. These modifications include IGF muteins produced by substituting or adding a cysteine in the amino acid sequence of native IGF as well as such muteins attached to polyethylene glycol (PEG) at the free cysteine site. The present invention further provides methods of making such modified forms. The IGF-PEG conjugates can be formulated into pharmaceutical compositions and used for the therapeutic treatment of IGF associated conditions. |
| priorityDate | 1994-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 310.